ATE541831T1 - Verwendung von indolderivaten als nurr-1- aktivatoren zur behandlung von morbus parkinson - Google Patents

Verwendung von indolderivaten als nurr-1- aktivatoren zur behandlung von morbus parkinson

Info

Publication number
ATE541831T1
ATE541831T1 AT09784501T AT09784501T ATE541831T1 AT E541831 T1 ATE541831 T1 AT E541831T1 AT 09784501 T AT09784501 T AT 09784501T AT 09784501 T AT09784501 T AT 09784501T AT E541831 T1 ATE541831 T1 AT E541831T1
Authority
AT
Austria
Prior art keywords
nurr
activators
parkinson
disease
treatment
Prior art date
Application number
AT09784501T
Other languages
English (en)
Inventor
Benaissa Boubia
Vliet Bernard Van
Hartog Jacobus Den
Andrew Mccreary
Mireille Tallandier
Dongen Maria Van
Olivia Poupardin-Olivier
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Application granted granted Critical
Publication of ATE541831T1 publication Critical patent/ATE541831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT09784501T 2008-07-10 2009-07-09 Verwendung von indolderivaten als nurr-1- aktivatoren zur behandlung von morbus parkinson ATE541831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0854712A FR2933609B1 (fr) 2008-07-10 2008-07-10 Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
PCT/FR2009/051372 WO2010004221A2 (fr) 2008-07-10 2009-07-09 Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson

Publications (1)

Publication Number Publication Date
ATE541831T1 true ATE541831T1 (de) 2012-02-15

Family

ID=40297845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09784501T ATE541831T1 (de) 2008-07-10 2009-07-09 Verwendung von indolderivaten als nurr-1- aktivatoren zur behandlung von morbus parkinson

Country Status (27)

Country Link
US (1) US8575210B2 (de)
EP (1) EP2300424B1 (de)
JP (1) JP5396650B2 (de)
KR (1) KR101606184B1 (de)
CN (1) CN102112441B (de)
AR (1) AR072718A1 (de)
AT (1) ATE541831T1 (de)
AU (1) AU2009269842B2 (de)
BR (1) BRPI0915627A8 (de)
CA (1) CA2730302C (de)
CY (1) CY1112638T1 (de)
DK (1) DK2300424T3 (de)
EA (1) EA018079B1 (de)
ES (1) ES2381180T3 (de)
FR (1) FR2933609B1 (de)
HR (1) HRP20120231T1 (de)
IL (1) IL210386A (de)
MX (1) MX2011000353A (de)
MY (1) MY155959A (de)
PL (1) PL2300424T3 (de)
PT (1) PT2300424E (de)
SA (1) SA109300453B1 (de)
SI (1) SI2300424T1 (de)
TW (1) TWI414289B (de)
UA (1) UA102397C2 (de)
WO (1) WO2010004221A2 (de)
ZA (1) ZA201100041B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2955108B1 (fr) * 2010-01-08 2012-03-16 Fournier Lab Sa Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
EP2487159A1 (de) * 2011-02-11 2012-08-15 MSD Oss B.V. RORgammaT-Hemmer
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
CA3138439C (en) 2017-11-15 2023-05-23 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
KR102059160B1 (ko) 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
KR101964889B1 (ko) 2017-11-17 2019-04-02 한국생명공학연구원 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
KR20240020098A (ko) 2022-08-05 2024-02-14 엠테라파마 주식회사 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438586A1 (en) * 2001-03-14 2002-09-19 Eli Lilly And Company Retinoid x receptor modulators
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP1689389A4 (de) * 2003-12-04 2009-06-17 Nat Health Research Institutes Indol-verbindungen
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903106B1 (fr) * 2006-07-03 2010-07-30 Sanofi Aventis Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HK1154852A1 (en) 2012-05-04
DK2300424T3 (da) 2012-04-16
UA102397C2 (ru) 2013-07-10
IL210386A0 (en) 2011-03-31
CN102112441A (zh) 2011-06-29
PT2300424E (pt) 2012-04-27
BRPI0915627A8 (pt) 2017-05-16
EP2300424A2 (de) 2011-03-30
PL2300424T3 (pl) 2012-06-29
AU2009269842B2 (en) 2013-08-22
EA201170150A1 (ru) 2011-06-30
TW201006468A (en) 2010-02-16
SA109300453B1 (ar) 2013-05-18
US8575210B2 (en) 2013-11-05
BRPI0915627A2 (pt) 2016-07-26
WO2010004221A2 (fr) 2010-01-14
JP5396650B2 (ja) 2014-01-22
EP2300424B1 (de) 2012-01-18
CA2730302A1 (fr) 2010-01-14
TWI414289B (zh) 2013-11-11
CY1112638T1 (el) 2016-02-10
JP2011527326A (ja) 2011-10-27
CA2730302C (fr) 2017-03-07
AR072718A1 (es) 2010-09-15
IL210386A (en) 2015-09-24
KR101606184B1 (ko) 2016-03-24
MY155959A (en) 2015-12-31
FR2933609B1 (fr) 2010-08-27
AU2009269842A1 (en) 2010-01-14
WO2010004221A3 (fr) 2010-05-06
CN102112441B (zh) 2013-07-10
US20110178150A1 (en) 2011-07-21
KR20110110759A (ko) 2011-10-07
SI2300424T1 (sl) 2012-04-30
HRP20120231T1 (hr) 2012-04-30
EA018079B1 (ru) 2013-05-30
ZA201100041B (en) 2012-03-28
FR2933609A1 (fr) 2010-01-15
MX2011000353A (es) 2011-02-22
ES2381180T3 (es) 2012-05-23

Similar Documents

Publication Publication Date Title
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
UA107445C2 (uk) 5-фторпіримідинові похідні як фунгіциди
ZA200907137B (en) Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ZA201100041B (en) Use of indole derivatives as nurr-1 activators for treating parkinson's disease
EP2320939A4 (de) Gewebe-kallikrein zur behandlung der parkinson-krankheit
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
EP2349308A4 (de) Verbindungen zur behandlung von morbus alzheimer
ITRM20080546A1 (it) Sedia ginnica per la stimolazione dell'apparato muscolo-scheletrico
ATE513548T1 (de) Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy-)pyridi - 2-carboxamid zur behandlung motorischer störungen aufgrund der parkinsonschen krankheit
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
IL218526A0 (en) Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease
DE502006004733D1 (de) Verfahren zur herstellung von losartan
IL208127A0 (en) Ptph1 inhibitors for the treatment of alzheimer's disease
ATE511394T1 (de) Verwendung von phthalocyanin-derivaten zur nicht- photodynamischen behandlung von erkrankungen